GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » Price-to-Owner-Earnings

Advagene Biopharma Co (ROCO:6709) Price-to-Owner-Earnings : (As of Sep. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co Price-to-Owner-Earnings?

As of today (2024-09-25), Advagene Biopharma Co's share price is NT$24.70. Advagene Biopharma Co does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Advagene Biopharma Co's Price-to-Owner-Earnings or its related term are showing as below:


ROCO:6709's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.02
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-09-25), Advagene Biopharma Co's share price is NT$24.70. Advagene Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-1.48. Therefore, Advagene Biopharma Co's PE Ratio for today is At Loss.

As of today (2024-09-25), Advagene Biopharma Co's share price is NT$24.70. Advagene Biopharma Co's EPS without NRI for the trailing twelve months (TTM) ended in was NT$-1.48. Therefore, Advagene Biopharma Co's PE Ratio without NRI for today is At Loss.


Advagene Biopharma Co Price-to-Owner-Earnings Historical Data

The historical data trend for Advagene Biopharma Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co Price-to-Owner-Earnings Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Advagene Biopharma Co's Price-to-Owner-Earnings

For the Biotechnology subindustry, Advagene Biopharma Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advagene Biopharma Co's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advagene Biopharma Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Advagene Biopharma Co's Price-to-Owner-Earnings falls into.



Advagene Biopharma Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Advagene Biopharma Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=24.70/-1.63
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advagene Biopharma Co  (ROCO:6709) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Advagene Biopharma Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Advagene Biopharma Co Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co Headlines

No Headlines